

line 29, replace "p(325)-gHFIF-4" with
-- p[325]-gHFIF4 --;
line 32, replace "pHFIF-21" with
-- pHFIF21 --.
Page 94, line 2, replace "pHFIF-21" with
-- pHFIF21 --;
line 35, replace "(p[325]-gHFIF-4)" with
-- (p[325]-gHFIF4) --.

IN THE CLAIMS

Kindly delete claim 29.

Add new claims 31-34 as follows:

31. A method for treating human cancers or tumors comprising administering a therapeutically effective amount of a composition comprising:

a polypeptide substantially free of other proteins with which it is normally associated produced by a host transformed by a recombinant DNA molecule characterized by a DNA sequence selected from the group consisting of:

- (a) DNA sequences which hybridize to any of the DNA inserts of G-pBR322(Pst)/HFIF1, G-pBR322(Pst)/HFIF3 (DSM 1791), G-pBR322(Pst)/HFIF6 (DSM 1792), and G-pBR322(Pst)/HFIF7 (DSM 1793), and which code for a polypeptide displaying antiviral activity, and
 - (b) DNA sequences which are degenerate as a result of the genetic code to the DNA sequences defined in (a);
- said DNA sequence being operatively linked to an expression control sequence in the recombinant DNA molecule.

32. A method for treating human cancers or tumors comprising administering a therapeutically effective amount of a composition comprising:

a polypeptide substantially free of other proteins with which it is normally associated characterized in that it is coded for by a DNA sequence selected from the group consisting of:

- (a) DNA sequences which hybridize to any of the DNA inserts of G-pBR322(Pst)/HFIF1, G-pBR322(Pst)/HFIF3 (DSM 1791), G-pBR322(Pst)/HFIF6 (DSM 1792), and G-pBR322(Pst)/HFIF7 (DSM 1793), and which code for a polypeptide displaying antiviral activity, and
- (b) DNA sequences which are degenerate as a result of the genetic code to the DNA sequences defined in (a) said DNA sequence being operatively linked to an expression control sequence in the recombinant DNA molecule.

33. The method according to claim 31 or 32, wherein said DNA sequence is selected from DNA sequences of the formulae:

ATGACCAACAAGTGTCTCCTCCAAATTGCTCTCCTGTTGTGCTTCTCCACTACAGCT
CTTTCCATGAGCTACAACCTTGCTTGGATTCTTACAAAGAAGCAGCAATTTTCAGTGT
CAGAAGCTCCTGTGGCAATTGAATGGGAGGCTTGAATACTGCCTCAAGGACAGGATG
AACTTTGACATCCCTGAGGAGATTAAGCAGCTGCAGCAGTTCCAGAAGGAGGACGCC
GCATTGACCATCTATGAGATGCTCCAGAACATCTTTGCTATTTTCAGACAAGATTCA
TCTAGCACTGGCTGGAATGAGACTATTGTTGAGAACCTCCTGGCTAATGTCTATCAT
CAGATAAACCATCTGAAGACAGTCCTGGAAGAAAACTGGAGAAAGAAGATTTCCACC
AGGGGAAAACTCATGAGCAGTCTGCACCTGAAAAGATATTATGGGAGGATTCTGCAT
TACCTGAAGGCCAAGGAGTACAGTCACTGTGCCTGGACCATAGTCAGAGTGGAAATC
CTAAGGAACTTTTACTTCATTAACAGACTTACAGGTTACCTCCGAAAC, and ATG
AGCTACAACCTTGCTTGGATTCTTACAAAGAAGCAGCAATTTTCAGTGTGAGAAGCTC

CTGTGGCAATTGAATGGGAGGCTTGAATACTGCCTCAAGGACAGGATGAACTTTGAC
 ATCCCTGAGGAGATTAAGCAGCTGCAGCAGTTCCAGAAGGAGGACGCCGCATTGACC
 ATCTATGAGATGCTCCAGAACATCTTTGCTATTTTCAGACAAGATTCATCTAGCACT
 GGCTGGAATGAGACTATTGTTGAGAACCTCCTGGCTAATGTCTATCATCAGATAAAC
 CATCTGAAGACAGTCCTGGAAGAAAACTGGAGAAAGAAGATTTACCAGGGGAAAA
 CTCATGAGCAGTCTGCACCTGAAAAGATATTATGGGAGGATTCTGCATTACCTGAAG
 GCCAAGGAGTACAGTCACTGTGCCTGGACCATAGTCAGAGTGGAAATCCTAAGGAAC
 TTTTACTTCATTAACAGACTTACAGGTTACCTCCGAAAC.

34. The method according to claim 31 ~~or 32~~ wherein the polypeptide is selected from polypeptides of the formulae:
 Met-Thr-Asn-Lys-Cys-Leu-Leu-Gln-Ile-Ala-Leu-Leu-Leu-Cys-Phe-
 Ser-Thr-Thr-Ala-Leu-Ser-Met-Ser-Tyr-Asn-Leu-Leu-Gly-Phe-Leu-
 Gln-Arg-Ser-Ser-Asn-Phe-Gln-Cys-Gln-Lys-Leu-Leu-Trp-Gln-Leu-
 Asn-Gly-Arg-Leu-Glu-Tyr-Cys-Leu-Lys-Asp-Arg-Met-Asn-Phe-Asp-
 Ile-Pro-Glu-Glu-Ile-Lys-Gln-Leu-Gln-Gln-Phe-Gln-Lys-Glu-Asp-
 Ala-Ala-Leu-Thr-Ile-Tyr-Glu-Met-Leu-Gln-Asn-Ile-Phe-Ala-Ile-
 Phe-Arg-Gln-Asp-Ser-Ser-Ser-Thr-Gly-Trp-Asn-Glu-Thr-Ile-Val-
 Glu-Asn-Leu-Leu-Ala-Asn-Val-Tyr-His-Gln-Ile-Asn-His-Leu-Lys-
 Thr-Val-Leu-Glu-Glu-Lys-Leu-Glu-Lys-Glu-Asp-Phe-Thr-Arg-Gly-
 Lys-Leu-Met-Ser-Ser-Leu-His-Leu-Lys-Arg-Tyr-Tyr-Gly-Arg-Ile-
 Leu-His-Tyr-Leu-Lys-Ala-Lys-Glu-Tyr-Ser-His-Cys-Ala-Trp-Thr-
 Ile-Val-Arg-Val-Glu-Ile-Leu-Arg-Asn-Phe-Tyr-Phe-Ile-Asn-Arg-
 Leu-Thr-Gly-Tyr-Leu-Arg-Asn, and Met-Ser-Tyr-Asn-Leu-Leu-Gly-
 Phe-Leu-Gln-Arg-Ser-Ser-Asn-Phe-Gln-Cys-Gln-Lys-Leu-Leu-Trp-
 Gln-Leu-Asn-Gly-Arg-Leu-Glu-Tyr-Cys-Leu-Lys-Asp-Arg-Met-Asn-
 Phe-Asp-Ile-Pro-Glu-Glu-Ile-Lys-Gln-Leu-Gln-Gln-Phe-Gln-Lys-
 Glu-Asp-Ala-Ala-Leu-Thr-Ile-Tyr-Glu-Met-Leu-Gln-Asn-Ile-Phe-
 Ala-Ile-Phe-Arg-Gln-Asp-Ser-Ser-Ser-Thr-Gly-Trp-Asn-Glu-Thr-
 Ile-Val-Glu-Asn-Leu-Leu-Ala-Asn-Val-Tyr-His-Gln-Ile-Asn-His-
 Leu-Lys-Thr-Val-Leu-Glu-Glu-Lys-Leu-Glu-Lys-Glu-Asp-Phe-Thr-